FDA Fast-Tracks Cannabis Drug Shown to Beat Opioids

A cannabis drug from Germany just cleared one of the highest bars in American medicine. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, a pharmaceutical-grade, full-spectrum cannabis extract targeting chronic low back pain. Behind that designation sits clinical data that is hard to ignore, including a direct head-to-head comparison with opioids that VER-01 won.

A Drug Built Like No Other Cannabis Product

VER-01 is not a CBD tincture. It is not a recreational cannabis extract with a medical label slapped on it.

It is a standardized, pharmaceutical-grade, full-spectrum extract derived from a proprietary Cannabis sativa strain called DKJ127 L., purpose-built and selected specifically for chronic pain treatment. Its formulation contains a defined blend of cannabinoids, terpenes, and bioactive compounds, including cannabigerol, beta-caryophyllene, and alpha-bisabolol, all chosen for their potential role in pain modulation. It is taken orally as liquid drops.

Every batch is tested using advanced chromatographic and spectrometric methods to guarantee consistent quality and composition. Vertanical, the German pharmaceutical company behind the drug and part of the FUTRUE Group, founded by Dr. Clemens Fischer, has been explicit on one point: the results from VER-01 clinical trials cannot be applied to any other cannabis product because the chemistry is entirely unique to this formulation.

The Opioid Gap That Made VER-01 Necessary

Chronic low back pain affects roughly 540 million people worldwide. It consistently ranks as one of the leading causes of disability in working-age adults globally, and back pain that lingers beyond three months qualifies as chronic.

In the United States alone, the scale of the crisis is staggering:

• 25 million Americans live with high-impact chronic pain
• Over 20% of adults with chronic pain currently use opioids
• Nearly 9 million Americans reported misusing prescription opioids in 2022, according to the CDC
• Chronic low back pain is second only to cancer in the volume of opioids prescribed

Current pharmacological options remain largely stuck between NSAIDs and opioids, both of which carry serious long-term safety risks, addiction potential, and significant side effects.

That treatment gap is exactly what Vertanical built VER-01 to fill.

What Two Phase 3 Trials Proved

The first trial was a placebo-controlled, double-blind Phase 3 study enrolling 820 patients across 66 sites in Germany and Austria. Published in Nature Medicine in September 2025, the study ran for 12 weeks, then continued through a six-month open-label extension and a further six-month withdrawal phase.

At the start of the trial, participants reported moderate to severe pain, averaging a score of around 6 on the Numeric Rating Scale. Over 22% had a neuropathic pain component.

The VER-01 group saw a mean pain reduction of 1.9 points from baseline. That outperformed placebo by 0.6 points on the scale. For patients with a neuropathic pain component, the benefit gap was even wider.

The drug also moved the needle on quality of life. Participants in the VER-01 group reported meaningful improvements in sleep quality and physical function. Scores on a standard disability questionnaire improved by 3.1 points in the VER-01 group, compared to 2.0 in the placebo group.

VER-01 showed no signs of dependence or withdrawal across the entire study period. Mild to moderate side effects like dizziness and headache did occur, but most appeared only during the initial three-week titration phase and resolved on their own.

The second Phase 3 trial, known as ELEVATE, went further. In a direct comparison with opioids, VER-01 demonstrated superior pain reduction and better gastrointestinal tolerability.

Prof. Roger Knaggs, Professor of Pain Management and President of the British Pain Society, said the two Phase 3 studies show VER-01 “could be a transformative therapy” for patients and physicians who have long sought new options.

An FDA Designation at a Historic Moment

On May 18, 2026, the FDA formally granted VER-01 Breakthrough Therapy Designation. This is not approval. What it means is that the FDA sees enough clinical evidence to put VER-01 on its fastest development and review track.

The timing carries real weight. The designation arrived just weeks after the U.S. officially moved medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. In April 2026, Acting Attorney General Todd Blanche placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, following a December 2025 executive order from President Trump directing the reclassification process. A full DEA rulemaking hearing on broader rescheduling is set to begin June 29, 2026.

Schedule III status formally recognizes accepted medical use and lower abuse potential, placing cannabis alongside substances like ketamine for the first time in over 50 years of federal drug policy.

“Patients have waited far too long for meaningful progress. We believe VER-01 has the potential to change how chronic pain is treated and offer physicians a much-needed non-opioid solution.” — Dr. Clemens Fischer, CEO of FUTRUE Group and Founder of Vertanical

Fischer also called the FDA designation “a major recognition of its potential to address the significant unmet need in chronic pain.”

What Comes Next for Patients in Europe and the U.S.

Vertanical is already preparing to launch VER-01 in its first European markets within weeks. Germany is expected to move first. Once Germany grants marketing authorization as an approved medicinal product, the EU mutual recognition procedure opens the route to broader access across the continent.

The U.S. path is longer. A separate Phase 3 trial has been launched specifically to meet American regulatory requirements, with the goal of confirming VER-01’s safety and effectiveness in U.S. patients with chronic low back pain.

U.S. Milestone	Expected Year
Phase 3 Data Readout	2027
New Drug Application Filed	2028
Potential FDA Approval	Post-2028

U.S. approval, if it comes, remains years away. This will be a prescription-only medication, not available through dispensaries.

But the Breakthrough Therapy Designation sends a clear message: the FDA considers the science behind VER-01 serious enough to move fast.

For the tens of millions of people navigating daily chronic back pain, often cycling through inadequate relief and real fears about opioid dependence, VER-01 arriving at this moment feels like a genuine turning point. The rescheduling of cannabis and this clinical breakthrough have landed at nearly the same time, and together they are reshaping a conversation about pain management that has been stuck for decades. Whether full FDA approval follows or not, the door to a post-opioid approach to chronic pain has opened a little wider, and patients around the world are paying close attention.

Do you think cannabis-based medicines like VER-01 could replace opioids as a first-line treatment for chronic pain? Drop your thoughts in the comments below.